menu
    • menu
    [{"orgOrder":0,"company":"PentixaPharm","sponsor":"Glycotope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"GT-001","moa":"","graph1":"Technology","graph2":"Approved","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"PentixaPharm \/ Pentixapharm","highestDevelopmentStatusID":"12","companyTruncated":"PentixaPharm \/ Pentixapharm"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"BankM AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Y90-PentixaTher","moa":"","graph1":"Technology","graph2":"Approved","graph3":"PentixaPharm","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"PentixaPharm \/ BankM AG","highestDevelopmentStatusID":"12","companyTruncated":"PentixaPharm \/ BankM AG"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lu177-PentixaTher","moa":"","graph1":"Technology","graph2":"Approved","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"PentixaPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PentixaPharm \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by PentixaPharm

    Menu

    PentixaPharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PentixaPharm

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lu177-PentixaTher

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lu177-PentixaTher Trial Begins for AML and ALL, Supporting Radiotherapy Evidence

                            Details : Lu177-PentixaTher is a novel radiopharmaceutical therapy, being investigated in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

                            Brand Name : [90Y]Y-PTT

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 21, 2024

                            Lead Product(s) : Lu177-PentixaTher

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PentixaPharm

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Y90-PentixaTher

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BankM AG

                            Deal Size : $22.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Pentixapharm Scores $22M in IPO to Advance Radiopharma Trials

                            Details : The proceeds will focus on the clinical development and approval of company's lead candidates Ga68-PentixaFor and Y90-PentixaTher.

                            Brand Name : Y90-PentixaTher

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 03, 2024

                            Lead Product(s) : Y90-PentixaTher

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BankM AG

                            Deal Size : $22.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PentixaPharm

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GT-001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Glycotope

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pentixapharm Acquires Target Discovery Business of Glycotope

                            Details : Through the acquisition, Pentixapharm will leverage the Glycotype portfolio of preclinical antibodies against multiple oncology including GT-001, which is being evaluated for breast and lung cancer.

                            Brand Name : GT-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 03, 2024

                            Lead Product(s) : GT-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Glycotope

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth